Company intelligence / Profile preview

Exela Pharma Sciences

Lenoir, North Carolina, United Statesexelapharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Exela Pharma Sciences has multiple FDA-approved sterile injectable products on the market, including both proprietary and generic drugs. The company has developed several first-to-market generics and continues to expand its portfolio with a focus on high-barrier-to-entry hospital products. It also operates as a CDMO for external clients. Recent recalls have occurred but are not unusual in the industry.

Therapeutic areas: HematologyCardiovascularNeurologyMetabolic Disorders
Modalities: Small moleculeBiologic (sterile injectables)
Industry: Biotech

Drug pipeline

1 asset

Cysteine

Approved

Partnerships

Eton Pharmaceuticals has filed ANDAs referencing some of Exela’s products; other partnerships likely via CDMO business but not specifically named in public sources.

Beyond the preview

Go deeper on Exela Pharma Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exela Pharma Sciences.

Explore the full profile